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Summary
FIP1L1-PDGFR causes hypereosinophilic syndrome (HES) and is inhibited by the tyrosine kinase inhibitor imatinib
(Gleevec). Imatinib is a potent inhibitor of ABL, ARG, PDGFR, PDGFR, and KIT and induces durable hematologic responses
in HES patients. However, we observed relapse with resistance to imatinib as consequence of a T674I mutation in FIP1L1-
PDGFR, analogous to the imatinib-resistant T315I mutation in BCR-ABL. We developed a murine bone marrow transplant
model of FIP1L1-PDGFR-induced myeloproliferative disease to evaluate the efficacy of PKC412, an alternative inhibitor
of PDGFR, for the treatment of HES. PKC412 is effective for treatment of FIP1L1-PDGFR-induced disease and of imatinib-
induced resistance due to the T674I mutation. Our data establish PKC412 as molecularly targeted therapy for HES and
other diseases expressing activated PDGFR and demonstrate the potential of alternative kinase inhibitors to overcome
resistance in target tyrosine kinases.
Introduction An unexpected dividend of these pioneering efforts to dem-
onstrate the value of molecular-targeted therapy of CML has
Small molecule inhibitors of tyrosine kinases have emerged as been the observation that imatinib has efficacy in other challeng-
effective therapies for hematologic malignancies as well as solid ing clinical cancer contexts. For example, the observation that
tumors (Cohen, 2002; Fabbro et al., 2002). Perhaps the best- the majority of gastrointestinal stromal cell tumors (GIST) harbor
characterized example is the application of imatinib, a selective activating mutations in KIT led to clinical trials that demonstrated
inhibitor of the ABL, ARG, PDGFR, PDGFR, and KIT tyrosine
remarkable activity of imatinib in this context (Demetri et al.,kinases, in the treatment of BCR-ABL-positive CML and CML
2002). Similarly, chronic myelomonocytic leukemias (CMML) as-in blast crisis (Capdeville et al., 2002). Imatinib is safe and effi-
sociated with the constitutively activated TEL-PDGFR fusioncacious in this context (Druker et al., 2001a, 2001b), and it has
are also highly responsive to treatment with imatinib (Apperleybeen suggested that imatinib should now be considered as the
first line therapy of choice for chronic phase CML (Druker, 2003). et al., 2002).
S I G N I F I C A N C E
Imatinib is an effective, molecular-targeted therapy for BCR-ABL-positive CML. However, the development of clinical resistance to
imatinib due to point mutations in the ABL kinase domain has emerged as an increasingly important problem. As a class of new
therapeutic agents, a considerable variety of small molecule inhibitors of tyrosine kinases are currently under development as
therapeutics for both hematological malignancies and solid tumors. Here we provide proof of principle that resistance to imatinib
as consequence of point mutation in PDGFR can be overcome by the use of an alternative PDGFR inhibitor, PKC412. Our results
indicate that the use of structurally diverse small molecule inhibitors that target the same tyrosine kinase, but employ different binding
modes, can be an effective approach in circumventing or preventing development of resistance.
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Figure 1. PKC412 directly inhibits FIP1L1-PDGFR in vitro
A: Constructs used in this study. The stars mark the positions of the T674I and N659D mutations.
LTR, long terminal repeat. IRES, internal ribosomal entry site. EGFP, enhanced green fluorescent protein.
B: Dose response curves of Ba/F3 cells stably expressing wild-type, T674I, or N659D FIP1L1-PDGFR. The percentage of growth, relative to the growth of cells
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Imatinib therapy of CML, GIST, and CMML are examples PDGFR (Andrejauskas-Buchdunger and Regenass, 1992; Fab-
of rational clinical trial design based on the presence of muta- bro et al., 1999, 2000; Weisberg et al., 2002). To determine
tions in tyrosine kinases that are known targets of imatinib. whether PKC412 inhibited FIP1L1-PDGFR, we investigated
However, imatinib has also been used to treat a spectrum of the dose-response relationship for Ba/F3 cells stably expressing
diseases for which the molecular basis of disease is not known. the fusion protein. Ba/F3 is a murine hematopoietic cell line that
One example is the use of imatinib to treat hypereosinophilic requires IL3 for growth, but activated kinases including BCR-
syndrome (HES), a myeloproliferative disease that most promi- ABL and FIP1L1-PDGFR transform Ba/F3 cells to growth fac-
nently affects the eosinophil lineage (Gleich et al., 2002; Ault et tor independence (Daley and Baltimore, 1988; Cools et al.,
al., 2002; Pardanani et al., 2002; Cortes et al., 2003). Based on
2003). We have previously reported that imatinib inhibits thethe clinical observation that a majority of HES patients have
growth of FIP1L1-PDGFR-expressing Ba/F3 cells with a cellu-dramatic clinical response to imatinib, we investigated the pos-
lar IC50 of 3 nM (Cools et al., 2003). PKC412 also inhibited thesibility that one or more known targets of imatinib was the cause
growth of these cells with a cellular IC50 of approximately 130of HES. We discovered a novel FIP1L1-PDGFR fusion protein,
nM (Figure 1). Addition of IL3 to the growth media restored cellexpressed as consequence of interstitial chromosomal deletion
growth in the presence of PKC412, indicating that PKC412on 4q12, in the majority of patients with HES (Cools et al., 2003).
FIP1L1-PDGFR-positive HES patients achieve rapid and dura- inhibition was not due to nonspecific toxicity (data not shown).
ble clinical responses to imatinib, and FIP1L1-PDGFR is po- We next introduced a point mutation into the ATP binding pocket
tently inhibited by imatinib in vitro. Furthermore, definitive evi- of PDGFR at asparagine residue 659 (FIP1L1-PDGFR(N659D))
dence for FIP1L1-PDGFR as the therapeutic target of imatinib that was predicted to result in resistance to PKC412 (J.C. and
in HES came from the identification of a T674I imatinib resis- D.G.G., unpublished data). Ba/F3 cells transformed with
tance mutation in the kinase domain of FIP1L1-PDGFR in a FIP1L1-PDGFR(N659D) were not inhibited at concentrations
patient who relapsed while on therapy (Cools et al., 2003). The of PKC412 as high as 400 nM, and a cellular IC50 could not becatalytic sites of tyrosine kinases are highly conserved, and the
achieved (Figure 1). These data indicate that the N659D muta-T674I mutation in PDGFR corresponds to the T315I mutation
tion in the context of FIP1L1-PDGFR confers resistance toin ABL, a common resistance mutation in BCR-ABL-positive
PKC412 and that the growth inhibitory effects of PKC412 forCML patients that relapse while on imatinib therapy (Gorre et
cells transformed by the wild-type FIP1L1-PDGFR were spe-al., 2001; Shah et al., 2002). In summary, our previous results
cifically due to inhibition of the fusion protein. These observa-demonstrate that FIP1L1-PDGFR is specifically inhibited by
tions correlated with the IC50 for inhibition of FIP1L1-PDGFRimatinib, and that the T674I mutation in the PDGFR kinase
tyrosine kinase activity as assessed by reduction in tyrosinedomain confers resistance to imatinib as does the T315I muta-
tion in the context of BCR-ABL. phosphorylation content of the fusion protein as well as its
PKC412 is a selective inhibitor of FLT3, PKC, KDR, KIT, downstream target, Stat5. The IC50 of PKC412 for FIP1L1-
PDGFR, and PDGFR (Andrejauskas-Buchdunger and Regen- PDGFR or Stat5 was approximately 100 nM, and 400 nM
ass, 1992; Fabbro et al., 1999, 2000; Weisberg et al., 2002). for the N659D mutant (Figure 1).
The safety and pharmacokinetic profiles of PKC412 have been
determined in Phase I clinical trials (Propper et al., 2001), and
PKC412 inhibits the imatinib-resistantthis inhibitor is currently being evaluated in a Phase II clinical
FIP1L1-PDGFR(T674I) mutanttrial as molecular-targeted therapy for AML with activating muta-
We next investigated whether PKC412 was able to inhibittions in FLT3 (Stone et al., 2003). We investigated the potential
FIP1L1-PDGFR containing the T674I mutation conferring re-use of PKC412 as an alternative option for the treatment of
sistance to imatinib (Cools et al., 2003), and conversely, whetherFIP1L1-PDGFR-positive HES and as a strategy to overcome
the clinical resistance to imatinib. PKC412 is a potent inhibitor imatinib could inhibit FIP1L1-PDGFR containing the N659D
of the kinase activity of the FIP1L1-PDGFR fusion protein and mutation conferring resistance to PKC412. We observed that
inhibits FIP1L1-PDGFR-mediated transformation of hemato- PKC412 inhibited the FIP1L1-PDGFR(T674I) imatinib-resistant
poietic cells in vitro and in vivo. Of particular note, PKC412 mutant with a cellular IC50 of approximately 100 nM, whereas
retained full inhibitory activity against the imatinib-resistant imatinib inhibited the FIP1L1-PDGFR(N659D) PKC412-resis-
T674I mutant form of FIP1L1-PDGFR and may be of value to tant mutant with a cellular IC50 of approximately 50 nM (Figureovercome or prevent resistance to imatinib.
1). These data correlated with IC50 for inhibition of tyrosine kinase
activity by PKC412, as assessed by Western blot analysis ofResults
tyrosine phosphorylation of FIP1L1-PDGFR or Stat5 (Figure
1). Interestingly, these data indicate that PKC412 is a morePKC412 specifically inhibits wild-type FIP1L1-PDGFR
potent inhibitor of the FIP1L1-PDGFR(T674I) mutant than ofPKC412, a derivative of staurosporine (N-benzoyl-staurosporine),
is a potent inhibitor of PKC, FLT3, KIT, KDR, PDGFR, and wild-type FIP1L1-PDGFR.
in the absence of drug, is plotted for increasing concentrations of imatinib or PKC412, respectively.
C: Analysis of the phosphorylation status of FIP1L1-PDGFR (wild-type, T674I mutant, or N659D mutant). FIP1L1-PDGFR was immunoprecipitated from Ba/
F3 cells stably expressing the different constructs and incubated with increasing concentrations of PKC412. Detection was performed with anti-phosphotyro-
sine or anti-PDGFR (loading control).
D: Analysis of the phosphorylation status of the downstream effector STAT5. Western blotting was performed using whole cell lysates of Ba/F3 cells stably
expressing the different constructs and incubated with increasing concentrations of PKC412. Detection was done with anti-phospho-STAT5 or anti-STAT5b
(loading control).
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A mouse model for FIP1L1-PDGFR-induced ease characterized by marked leukocytosis and splenomegaly.
In contrast, mice transplanted with cells expressing the T674Imyeloproliferative disease
These results demonstrated that PKC412 is an effective in vitro mutant did not respond to imatinib and developed disease with
the same penetrance and latency as the placebo group (Tableinhibitor of the imatinib-resistant FIP1L1-PDGFR(T674I) mu-
tant identified in a patient with clinical resistance to imatinib. 1). These data correlate with the clinical responses to imatinib
in human HES associated with the FIP1L1-PDGFR fusion andTo test in vivo efficacy of PKC412 inhibition of FIP1L1-PDGFR,
we developed a mouse model for FIP1L1-PDGFR-induced the T674I resistance mutation (Cools et al., 2003) and validate
the model for evaluation of efficacy of PKC412.myeloproliferative disease. Briefly, bone marrow cells from do-
nor mice treated with 5-fluorouracil were transduced with retro-
virus containing the FIP1L1-PDGFRA fusion gene or related PKC412 is efficacious for the treatment of both
FIP1L1-PDGFR and imatinib-resistantmutants (constructs shown in Figure 1), followed by transplanta-
tion into lethally irradiated syngeneic recipients. All animals de- FIP1L1-PDGFR(T674I)-induced
myeloproliferative diseaseveloped a myeloproliferative disease characterized by periph-
eral blood leukocytosis (mean white blood cell counts (WBC)  The in vitro results demonstrated the ability of PKC412 to inhibit
both FIP1L1-PDGFR and the imatinib-resistant FIP1L1-654  103/ml) and splenomegaly (mean spleen weight 832 mg)
with a latency of 14–21 days and 100% penetrance. Histopatho- PDGFR(T674I) mutant. We next investigated the in vivo efficacy
of PKC412 for the treatment of myeloproliferative disease in-logic analysis demonstrated maturing myeloid hyperplasia in
the bone marrow dominated by an increase of all forms of the duced by FIP1L1-PDGFR or the imatinib-resistant FIP1L1-
PDGFR(T674I) mutant. Myeloproliferative disease was againgranulocyte lineage (neutrophils, eosinophils, and basophils),
effacement of splenic architecture and expansion of the red induced using retroviral vectors containing either the wild-type
or the T674I mutant form of FIP1L1-PDGFR. The recipientpulp by a similar population, and extramedullary hematopoiesis
with a predominance of granulocytic forms in the liver, lung, mice were divided into three groups that received imatinib,
PKC412, or placebo, respectively. In this study design, animalskidney, and Peyer’s patches (Figures 2A–2D, data not shown).
Although numerous eosinophils were observed in many mice were treated daily until one week after all the placebo-treated
mice had been sacrificed due to progressive disease. Animals(5% to 20% eosinophils in the peripheral blood), all cells within
the granulocytic lineage were increased, with neutrophils dem- in the placebo groups developed massive splenomegaly and
marked leukocytosis and were all sacrificed by day 22 (T674Ionstrating the greatest increase. Overall, the phenotype closely
resembled myeloproliferative disease induced by other constitu- mutant) or day 27 (wild-type FIP1L1-PDGFR).
In control arms, mice treated with imatinib or placebo reca-tively activated tyrosine kinase fusions, including BCR-ABL (Da-
ley et al., 1990), TEL-PDGFR (Tomasson et al., 2000), TEL- pitulated the observations described above, namely that
FIP1L1-PDGFR disease was sensitive to treatment with ima-JAK2 (Schwaller et al., 1998), and FLT3-ITD (Kelly et al., 2002a).
Flow cytometry of single cell suspensions from spleen and bone tinib whereas the FIP1L1-PDGFR(T674I)-induced disease was
imatinib resistant. In particular, all animals transplanted withmarrow cells confirmed the histologic findings of chronic myelo-
proliferative disease, with dramatic increase in Gr-1/Mac-1 bone marrow cells expressing FIP1L1-PDGFR that were
treated with imatinib were alive at the study endpoint (day 33)cells and few T or B cells (Figures 2E and 2F). As described in
more detail below, the FIP1L1-PDGFR(T674I) resistance muta- (Figure 3A) and had a marked reduction in spleen weight and
leukocyte count (Table 2). In contrast, mice treated with imatinib,tion induced myeloproliferative disease that was indistinguish-
able from the wild-type fusion protein. but transplanted with bone marrow cells expressing the FIP1L1-
PDGFR(T674I) imatinib-resistant mutation, developed disease
with the same penetrance and latency as the placebo-treatedValidation of the mouse model for the study
of PDGFR inhibitors animals (Figure 3B) and had increased spleen weights and leu-
kocyte counts comparable to placebo-treated animals (Table 2).Induction of myeloproliferative disease by FIP1L1-PDGFR in
the murine BMT assay, although not exclusively characterized In striking contrast to the effects observed with imatinib,
PKC412 was effective in treating myeloproliferative diseaseby prominent eosinophilia, provided a model system to test
the efficacy of PKC412 and imatinib for treatment of disease induced either by the FIP1L1-PDGFR or the FIP1L1-
PDGFR(T674I) mutant (Figures 3A and 3B). Most mice trans-induced by wild-type and mutant fusion proteins. Imatinib is
an effective therapy for hypereosinophilic syndrome associated planted with bone marrow cells expressing FIP1L1-PDGFR
that were treated with PKC412 did not develop myeloprolifera-with the wild-type FIP1L1-PDGFR fusion, and relapse on ima-
tinib has been associated with acquisition of a T674I mutation. tive disease, as assessed by spleen weight and WBC counts
(Table 2). There was a significant prolongation of their survivalTherefore, we first validated the mouse model by testing the
ability of imatinib to prolong survival in animals with myeloprolif- (Figure 3A) and a clear reduction of their spleen weights and
leukocyte counts compared to the placebo group (Table 2).erative disease induced either by the wild-type FIP1L1-PDGFR
or the FIPL1-PDGFR(T674I) mutant. PKC412 was also effective for treatment of myeloproliferative
disease induced by the FIP1L1-PDGFR(T674I) imatinib resis-Myeloproliferative disease was induced by retroviral vectors
containing either the wild-type or T674I mutant form of FIP1L1- tance mutation, producing a significant prolongation of survival
(Figure 3B) and reduction in spleen weight and leukocyte countPDGFR, and the recipient mice were treated by gavage with
imatinib (125 mg/kg/day in two divided doses) or placebo. Re- compared to placebo-treated animals (Table 2). Similar results
with imatinib and PKC412 treatment were obtained in a third,cipient mice that received bone marrow expressing the wild-
type FIP1L1-PDGFR did not develop disease as assessed by independent trial, confirming the efficacy of PKC412 for the
treatment of myeloproliferative disease caused by FIP1L1-spleen weight and WBC when treated with imatinib, whereas
placebo-treated mice rapidly developed myeloproliferative dis- PDGFR and FIP1L1-PDGFR(T674I) (data not shown).
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Figure 2. Mice transplanted with bone marrow cells expressing FIP1L1-PDGFR develop a myeloproliferative disease
A–D: Histopathology of the bone marrow (A, 100), spleen (B, 40), liver (C, 40), and lung (D, 20) of a mouse that developed a FIP1L1-PDGFR-induced
myeloproliferative disease, documenting myeloid infiltration.
E and F: Immunophenotype of cells from spleen (E) and bone marrow (F) of the same mouse, illustrating a high percentage of mature myeloid cells in
spleen and bone marrow.
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Table 2. Efficacy of PKC412 for the treatment of both FIP1L1-PDGFR- andTable 1. Efficacy of imatinib for the treatment of FIP1L1-PDGFR-induced
myeloproliferative disease, and resistance to FIP1L1-PDGFR(T674I)-induced FIP1L1-PDGFR(T674I)-induced myeloproliferative disease (trial 2)
disease (trial 1)
FIP1L1-PDGFR
FIP1L1-PDGFR FIP1L1-PDGFR
Placebo Imatinib PKC412wild-type T674I
Spleen weight (mg)
Mean 729 101 241Placebo Imatinib Imatinib
Spleen weight (mg) Median 690 99 199
Range 588–922 82–132 104–586Mean 832 111 801
Median 852 106 780 n 9 9 8
Range 667–922 93–140 700–1,007 WBC (106/ml)
n 8 8 6 Mean 534.1 4.8 12.7
Median 554.3 4.8 12.4WBC ( 106/ml)
Mean 654.4 6.0 496.5 Range 388.9–639.0 4.4–5.3 5.8–20.0
n 4 4 3Median 620.2 5.2 507.7
Range 593.8–773.0 4.6–9.4 434.6–535.8
FIP1L1-PDGFR T674In 5 7 4
Placebo Imatinib PKC412Spleen weights and white blood cell counts (WBC) of mice in the different
Spleen weight (mg)groups of trial 1, determined at time of death or at trial endpoint. n: number
Mean 743 649 157of mice analyzed.
Median 778 645 157
Range 556–803 543–785 90–217
n 7 8 9
WBC (106/ml)
Mean 493.2 548.2 3.8The effect of imatinib and PKC412 treatment was also con-
Median 460.6 591.5 3.1firmed by flow cytometry of single cell suspensions from spleen
Range 28.7–879.8 364.9–657.6 1.9–7.2
(Figure 4) and histopathologic analysis of bone marrow and n 5 7 6
spleen (Figure 5). We observed, consistent with in vitro data,
Spleen weights and white blood cell counts (WBC) of mice in the differentthat imatinib appeared to be somewhat more effective than groups of trial 2, determined at time of death or at trial endpoint. n: number
PKC412 for treatment of the disease induced by wild-type of mice analyzed.
FIP1L1-PDGFR (Figures 3 and 4; Table 2).
Taken together, our in vitro and in vivo data indicate that
PKC412 is an effective inhibitor of FIP1L1-PDGFR and
the clinically derived imatinib-resistant mutant, FIP1L1-
will be rapidly extended (Cohen, 2002; Fabbro et al., 2002).PDGFR(T674I).
However, to the extent that tyrosine kinase inhibitors are effec-
tive in treatment of disease, we can anticipate the developmentDiscussion
of resistance to single agents as has previously been observed
for virtually all antibiological agents including antimicrobial andSmall molecule inhibitors of tyrosine kinases are effective thera-
antiviral agents, and chemotherapy. A validated approach topeutic agents for both hematologic malignancies and solid tu-
mors, and it is likely that this paradigm for treatment of cancer preventing or circumventing resistance is the use of combina-
Figure 3. PKC412 increases survival in a murine
BMT model for disease induced by either FIP1L1-
PDGFR or the imatinib-resistant FIP1L1-
PDGFR(T674I) mutant
A: Kaplan Meier plot showing the disease-free
survival (y axis) of mice transplanted with bone
marrow cells expressing FIP1L1-PDGFR (wild-
type) and treated with placebo, imatinib, or
PKC412. There is a significant difference in sur-
vival between the drug-treated groups (imatinib
or PKC412) versus the placebo group. The drop
in the curve on day 33 reflects animals that ap-
peared healthy at sacrifice, but were found to
have moderately enlarged spleens at necropsy.
B: Kaplan Meier plot showing the disease-free
survival (y axis) of mice transplanted with bone
marrow cells expressing the imatinib-resistant
FIP1L1-PDGFR(T674I) mutant and treated with
placebo, imatinib, or PKC412. There is no differ-
ence in survival between imatinib treatment and
placebo, confirming in vivo resistance of the
T674I mutant to imatinib. There was, however, a
significant difference in survival between PKC412
treatment and placebo. The treatment period
and p values are indicated on the plots.
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Figure 4. Immunophenotype of spleen cells of placebo-, imatinib-, and PKC412-treated mice
A and B: FACS analysis of spleen cells taken at death or trial endpoint from mice with disease caused by FIP1L1-PDGFR (A) or the imatinib-resistant FIP1L1-
PDGFR(T674I) mutant (B). Shown is the percentage of GFP-positive (transformed) cells, myeloid cells, and B and T cells in spleens with or without drug
treatment. All viable cells analyzed were included in the statistical analysis including those located at the outer boundaries of the quadrants. Effective
treatment is illustrated by a decrease in GFP-positive cells, a reduction of Gr-1/Mac-1-positive cells, and an increase in B and T cells in the spleen.
tions of non-cross-resistant drugs that also have nonoverlap- circumvent other imatinib resistance mutations in BCR-ABL,
but none thus far have a pharmacokinetic and toxicity profileping or minimal toxicities. In the case of tyrosine kinase inhibi-
tors, such combinations would ideally include small molecule that would allow for clinical application, and there are none that
are effective for the BCR-ABL(T315I) mutant (La Rosee et al.,inhibitors which recognize different structural elements of the
target protein. 2002).
Here we report data from in vitro and in vivo models ofIn this report, we investigate this strategy in the context of
treatment of hypereosinophilic syndrome associated with the myeloproliferative disease induced by FIP1L1-PDGFR indicat-
ing that the imatinib-resistant BCR-ABL(T315I) equivalent in theFIP1L1-PDGFRA fusion (Cools et al., 2003). The cloning of the
fusion gene was fueled by the clinical observation that the major- context of FIP1L1-PDGFR(T674I) can be effectively inhibited
with PKC412. As a staurosporin derivative, in contrast to ima-ity of HES patients have dramatic responses to imatinib (Gleich
et al., 2002). Furthermore, the acquisition of an imatinib resis- tinib, this molecule is expected to inhibit PDGFRa by binding
within the ATP binding pocket of the active conformation of thetance mutation of FIP1L1-PDGFR in a patient while on imatinib
therapy provides convincing evidence that the fusion is the kinase, as observed, for example, in the case of CSK and CDK2
(Lamers et al., 1999; Toledo et al., 1997). PKC412 is also antherapeutic target of imatinib in HES (Cools et al., 2003). To-
gether, these data provide the foundation for development of attractive candidate for analysis in this context because it is
currently in a Phase II clinical trial as a FLT3 inhibitor and hasalternative small molecule inhibitors that target the imatinib re-
sistance mutation. The T674I mutation is precisely analogous an acceptable toxicity and safety profile (Propper et al., 2001;
Stone et al., 2003).to the T315I imatinib resistance mutation that occurs in the
context of BCR-ABL in CML and CML blast crisis (Gorre et al., We first demonstrated that FIP1L1-PDGFR and two related
mutants confer factor-independent growth to Ba/F3 cells. As2001; Shah et al., 2002). Consequently, it is highly probably
that imatinib binds to an inactive conformation of PDGFRa, expected, imatinib inhibits the FIP1L1-PDGFR wild-type, but
not the clinically derived imatinib resistance mutation FIP1L1-analogous to that through which it binds c-ABL. Inhibition of the
BCR-ABL(T315I) has proven to be a difficult problem. Significant PDGFR(T674I). PKC412, in contrast, inhibits both the wild-type
and the imatinib-resistant mutant T674I. The inhibitory effect ofprogress has been made in development of compounds that
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Figure 5. Histopathology of bone marrow and spleen of placebo-, imatinib-, and PKC412-treated mice
A and B: Histopathology of bone marrow (60) and spleen (60) from mice at death or trial endpoint with FIP1L1-PDGFR-induced disease (A) or FIP1L1-
PDGFR(T674I)-induced disease (B), after treatment with placebo, imatinib, or PKC412. Effective treatment is illustrated by reappearance of a variety of
cell types and fat in the bone marrow and reappearance of lymphoid cells in the spleen.
PKC412 is not observed in the presence of IL3, indicating that PDGFR in this context, we generated a FIP1L1-PDGFR(N659D)
mutation that we predicted would be PKC412 resistant basedinhibition is not due to nonspecific toxicity. However, PKC412,
like all tyrosine kinase inhibitors that target the highly conserved, on unpublished observations in the context of other tyrosine
kinases. FIP1L1-PDGFR(N659D) was PKC412 resistant, indi-active conformation of the enzymes, is selective but not com-
pletely specific and inhibits PKC, KDR, KIT, and FLT3 in addition cating that inhibition of Ba/F3 cells transformed by FIP1L1-
PDGFR could be attributed solely to inhibition of the fusionto PDGFR and PDGFR (Fabbro et al., 1999, 2000; Weisberg
et al., 2002). To formally test the specificity of PKC412 for FIP1L1- gene. Of considerable interest, as discussed below, the
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PKC412-resistant mutant retained full sensitivity in vitro to ima- Although imatinib and PKC412 inhibit a similar spectrum of
tyrosine kinases that includes PDGFR, PDGFR, and KIT, ima-tinib.
We next sought to develop a murine model of FIP1L1- tinib also inhibits ABL and ARG, while PKC412 inhibits PKC
and FLT3 (Fabbro et al., 1999, 2000; Capdeville et al., 2002;PDGFR-induced myeloproliferative disease to further test
these observations in vivo. When we transduced unselected Weisberg et al., 2002). Thus, there may be unacceptable toxici-
ties from using these agents in combination. To the extent thatbone marrow cells with retrovirus containing the FIP1L1-
PDGFRA gene, we observed a myeloproliferative phenotype these agents have nonoverlapping or minimal toxicities, it may
be most prudent to use these agents in combination at initiationsimilar to that observed with other constitutively activated tyro-
sine kinases such as BCR-ABL (Daley et al., 1990), FLT3-ITD of therapy.
Finally, our data indicate that PKC412 may be useful in(Kelly et al., 2002a), or TEL-PDGFR (Tomasson et al., 2000),
with leukocytosis and splenomegaly attributable to a dramatic treating any disease in humans associated with activating muta-
tions in PDGFR or PDGFR. These would include, but not beexpansion of Gr-1/Mac-1-positive cells. Histopathologically, all
members of the granulocyte lineage (neutrophils, eosinophils, limited to, gastrointestinal stromal cell tumors associated with
activating mutations in PDGFR (that are clinically resistant toand basophils) were markedly expanded. In general, the great-
est overall increase was noted in the neutrophilic forms, but imatinib) (Heinrich et al., 2003), myeloproliferative disease asso-
ciated with the BCR-PDGFR fusion gene (Baxter et al., 2002),most animals had absolute eosinophil counts over 1500/l. Hu-
man hypereosinophilic syndrome has a variable phenotype, with or myeloproliferative disease associated with PDGFRB fusion
genes, including TEL-PDGFR (Golub et al., 1994), HIP1-diagnostic criteria including a prolonged elevation of eosinophils
above 1500/l, though most patients have a more dramatic PDGFR (Ross et al., 1998), H4-PDGFR (Schwaller et al.,
2001), RABPT5-PDGFR (Magnusson et al., 2001), or a spec-elevation of their eosinophil count (Chusid et al., 1975; Weller
and Bubley, 1994). The bone marrow of HES patients is typically trum of other translocations associated with PDGFRB re-
arrangements (Baxter et al., 2003). In addition, although mostcomprised of 30%–60% eosinophilic precursors. Although the
total leukocyte may be normal, most patients also have an of these are imatinib sensitive, PKC412 may have use in these
contexts, as in HES, in either preventing or treating imatinibexpansion of neutrophil lineage cells in both bone marrow and
peripheral blood (Weller and Bubley, 1994). resistance mutations. In addition, it is plausible that PKC412
could be useful in treating or overcoming resistance in cancersWe first validated the model using imatinib therapy of dis-
ease induced either by the FIP1L1-PDGFR fusion or the ima- or noncancerous diseases associated with overexpression of
PDGFRA, including central nervous system tumors (MacDonaldtinib-resistant T674I mutant. We observed clinical outcome sim-
ilar to that in humans with HES, namely that disease induced et al., 2001). Lastly, FIP1L1-PDGFRA itself may be capable of
contributing to the pathogenesis of cancer in other tissues, asby the wild-type FIP1L1-PDGFR was effectively treated with
imatinib, whereas disease induced by the imatinib resistance has been observed with activating KIT mutations in both sys-
temic mastocystosis and gastrointestinal stromal cell tumorsmutation was not.
These data set the stage for the pivotal experiment to test (Nagata et al., 1995; Longley et al., 1996; Hirota et al., 1998).
Since FIP1L1 is ubiquitously expressed, it would be reasonablethe effect of PKC412 on the imatinib resistance mutant. PKC412
was effective in treating disease induced by the imatinib-resis- to screen for the FIP1L1-PDGFRA fusion in other tumors, espe-
cially since effective therapy is currently available.tant mutant FIP1L1-PDGFRT674I, although it appears to be
somewhat less effective than imatinib both in vitro and in vivo in
Experimental proceduresinhibition of the wild-type FIP1L1-PDGFR. One animal treated
with PKC412 developed a marked myeloproliferative disease.
Constructs
The reason for breakthrough of disease is not certain, but could The retroviral construct MSCV-FIP1L1-PDGFR-ires-EGFP and the corre-
include the development of resistance mutations analogous to sponding T674I mutant were described previously (Cools et al., 2003). The
the N659D, inadequate dosing, or increased clearance of the N659D mutation was introduced by PCR. Constructs are shown in Figure 1.
drug in this animal.
Cell culture and retroviral transductionThese observations provide proof-of-principle that acquired
293T cells were grown in DMEM supplemented with 10% FBS. Ba/F3 cellsresistance to one tyrosine kinase inhibitor can be overcome by
were grown in RPMI supplemented with 10% FBS and 1 ng/ml mouse IL-3.
use of an alternative, structurally unrelated inhibitor that binds Production of retroviral vectors and transduction was described (Schwaller
to the kinase domain in a different manner. As imatinib therapy et al., 1998). Transformed Ba/F3 cells were grown in the absence of IL3.
has been FDA approved and PKC412 is currently in Phase II The kinase inhibitors imatinib and PKC412 were stored as 10 mM stock
solutions in water (imatinib) or DMSO (PKC412). These inhibitors were dilutedtrials for other indications, it is plausible that this strategy can
in RPMI medium for use. For Western blotting, Ba/F3 cells were incubatedbe clinically tested soon. However, it is not clear whether it would
in the presence of imatinib for 90 min before lysis. For dose response curves,be best to treat with a single agent until resistance develops or
Ba/F3 cells were incubated for 24 hr in the presence of imatinib, and theto treat initially with combination therapy. A recent report that
number of viable cells at the start and end point was determined by use of the
imatinib-resistant mutations in BCR-ABL may exist prior to the Celltiter96AQueousone solution proliferation assay (Promega). Dose response
initiation of therapy suggests that the latter approach may be curves were fitted using the OriginPro 6.1 software (OriginLab).
more effective (Shah et al., 2002). The finding that some imatinib
Bone marrow transplantation and treatment of the animalsresistance mutations are PKC412 sensitive (T674I) while other
Balb/c mice were purchased from Taconic. Bone marrow transplant assaysmutations result in resistance to PKC412 but retain imatinib
(injecting 1  106 cells per recipient mouse) and drug treatment of the micesensitivity (N659D) also supports the use of concurrent combi-
were performed as described previously (Schwaller et al., 1998; Kelly et
nation therapy. al., 2002b; Weisberg et al., 2002). Imatinib (stored as powder at 4C) was
The feasibility of combination therapy will depend in part resuspended in a 0.5% methylcellulose (MC) solution in water prior to use.
PKC412 (6% w/w in Gelucire 44/14 (GC) (Gattefosse, France)) was storedon safety profiles for these selective, but not specific inhibitors.
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Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J.,at 4C as a waxy solid formulation. Prior to administration, the GC/PKC412
Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., et al.waxy solid mixture was melted in a 44C water bath and diluted with sterilized
(2002). Response to imatinib mesylate in patients with chronic myeloprolifer-deionized water. The animals were weighed on a regular basis to ensure
ative diseases with rearrangements of the platelet-derived growth factorthat a consistent dose (125 mg/kg/day for imatinib and 100 mg/kg/day for
receptor beta. N. Engl. J. Med. 347, 481–487.PKC412) of drug was administered. Dosing was performed every 12 hr for
imatinib and every 24 hr for PKC412 by oral gavage of a maximum volume Ault, P., Cortes, J., Koller, C., Kaled, E.S., and Kantarjian, H. (2002). Re-
of 150 l per animal using 22 gauge gavage needles (Hornbecks). Placebo sponse of idiopathic hypereosinophilic syndrome to treatment with imatinib
animals received the same volume of an MC or GC solution. Any animals mesylate. Leuk. Res. 26, 881–884.
with splenomegaly (spleen boundary detectable at the dorsal midline) or
Baxter, E.J., Hochhaus, A., Bolufer, P., Reiter, A., Fernandez, J.M., Senent,that were moribund were sacrificed and analyzed for signs of hematological
L., Cervera, J., Moscardo, F., Sanz, M.A., and Cross, N.C. (2002). Thedisease.
t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR toPeripheral blood was collected from the retroorbital cavity using a hepa-
PDGFRA. Hum. Mol. Genet. 11, 1391–1397.rinized glass capillary. Blood smears were stained with Wright and Giemsa.
Manual and automated (ADIVA 120 Hematology system, Bayer) total and Baxter, E.J., Kulkarni, S., Vizmanos, J.L., Jaju, R., Martinelli, G., Testoni, N.,
differential blood cell counts were performed. Histopathologic exam of rele- Hughes, G., Salamanchuk, Z., Calasanz, M.J., Lahortiga, I., et al. (2003).
vant organs (spleen, liver, heart, lungs, intestine, hindlimb bones, and kid- Novel translocations that disrupt the platelet-derived growth factor receptor
beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disor-neys) and preparation of single cell suspensions from spleen and bone
ders. Br. J. Haematol. 120, 251–256.marrow for flow cytometry were performed as described (Schwaller et al.,
1998).
Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002).
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Statistical analysis Nat. Rev. Drug Discov. 1, 493–502.
In comparing the survival time of the mice, all times were measured from
Chusid, M.J., Dale, D.C., West, B.C., and Wolff, S.M. (1975). The hypereosi-the day of bone marrow transplant, estimated by the method of Kaplan and
nophilic syndrome: analysis of fourteen cases with review of the literature.Meier, and assessed using the log rank test.
Medicine (Baltimore) 54, 1–27.
Histopathology Cohen, P. (2002). Protein kinases–the major drug targets of the twenty-first
Murine tissues were fixed for at least 72 hr in 10% neutral buffered formalin century? Nat. Rev. Drug Discov. 1, 309–315.
(Sigma), dehydrated in alcohol, cleared in xylene, and infiltrated with paraffin
Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J.,on an automated processor (Leica). The tissue sections (4 m) from paraffin-
Kutok, J., Clark, J., Galinsky, I., Griffin, J.D., et al. (2003). A tyrosine kinaseembedded tissue blocks were placed on charged slides and deparaffinized
created by fusion of the PDGFRA and FIP1L1 genes is a therapeutic targetin xylene, rehydrated through graded alcohol solutions, and stained with
of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348,hematoxylin and eosin.
1201–1214.
Immunoprecipitation and Western blotting Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., Rios,
Immunoprecipitation was performed using the anti-Myc antibody (Cell Sig- M.B., Letvak, L., Kaled, E.S., and Kantarjian, H. (2003). Efficacy of imatinib
naling) and Protein G agarose (Roche). Each precipitation was started from mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood,
in press. Published online February 20, 2003. DOI 10.1182/blood-2003-01-6  106 Ba/F3 cells stably expressing myc-tagged FIP1L1-PDGFR wild-
0081.type or T674I mutant. Cells were lysed in lysis buffer (Cell Signaling) con-
taining 1 mM Na3VO4, 20M phenylarsine oxide (Calbiochem), and complete Daley, G.Q., and Baltimore, D. (1988). Transformation of an interleukin
tablets (Roche). For Western blotting, Ba/F3 cells were collected by centrifu- 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-
gation and directly lysed in 1  loading buffer containing 2% SDS and specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA 85, 9312–9316.
40 M DTT (Cell Signaling), separated using 10%–12% SDS-PAGE, and
Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronictransferred to membranes. The antibodies used were: anti-phospho-STAT5
myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphiaand anti-phospho-tyrosine (P-Tyr-100/102) (Cell Signaling), anti-PDGFR
chromosome. Science 247, 824–830.(Upstate), anti-STAT5b (Santa-Cruz), anti-mouse-PO, and anti-rabbit-PO
(Amersham Pharmacia Biotech). Detection was performed using the Western Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenb-
Lightning system (Perkin Elmer). erg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek,
M., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastro-
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